SCHEMBL8235153

SCHEMBL8235153

Bc1ccc(I)c(CC(=O)O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.39
TDP1 Q9NUW8 2/20 0.35
CYP1A2 P05177 4/20 0.35
HSD17B10 Q99714 3/20 0.35
CYP2C9 P11712 3/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
SRC P12931 1/20 0.35
PTGS2 P35354 2/20 0.35
KDM4E B2RXH2 3/20 0.33
LMNA P02545 3/20 0.33
HPGD P15428 3/20 0.33
TSHR P16473 3/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
NFKB1 P19838 2/20 0.33
PMP22 Q01453 2/20 0.33
POLB P06746 2/20 0.33
HIF1A Q16665 2/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2560222 0.77 PTGDR2 (0.44) AKR1B1TDP1CYP1A2HSD17B10CYP2C9
SCHEMBL24801286 0.77 APEX1 (0.44) AKR1B1TDP1CYP1A2HSD17B10SRC
SCHEMBL17429595 0.77 KEAP1 (0.50) AKR1B1TDP1CYP2C9LMNAHPGD
SCHEMBL6036182 0.77 SRC (0.54) AKR1B1HSD17B10SRCPTGS2KDM4E
SCHEMBL14873536 0.77 AKR1B1 (0.44) AKR1B1TDP1CYP1A2HSD17B10CYP2C9
SCHEMBL17679979 0.75 KLF10 (0.31)
SCHEMBL6036424 0.74 ALDH1A1 (0.41) AKR1B1TDP1HSD17B10KDM4ELMNA
SCHEMBL12811136 0.73 CXCL8 (0.41) AKR1B1TDP1CYP1A2HSD17B10SRC
SCHEMBL3827119 0.73 RXRA (0.47) HSD17B10KDM4EHPGDALDH1A1MEN1
SCHEMBL7322443 0.73 HSD17B10 (0.68) CYP1A2HSD17B10CYP2C19KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7829584-B2 Pyridines and pyridine N-oxides as modulators of thrombin JANSSEN PHARMACEUTICA NV (BE) 2010-11-09 US disclosed
US-7829584-B2 Pyridines and pyridine N-oxides as modulators of thrombin JANSSEN PHARMACEUTICA NV (BE) 2010-11-09 US disclosed
US-20070225282-A1 PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN JANSSEN PHARMACEUTICA, N.V. (BE) 2007-09-27 US disclosed
US-20070225282-A1 PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN JANSSEN PHARMACEUTICA, N.V. (BE) 2007-09-27 US disclosed
WO-2007109459-A2 PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN JANSSEN PHARMACEUTICA, NV (BE) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225282-A1 PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN F2, F11, TBXAS1 AKR1B1 2156/4885TDP1 1002/4885CYP1A2 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.